Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery
09 mai 2024 07h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY Medtronic to fund...
ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY
12 mars 2024 07h30 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY Companies to combine proprietary...
First Product Incorporating Arecor’s Arestat Technology, At220, Launched in Europe
17 nov. 2023 02h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) FIRST PRODUCT INCORPORATING ARECOR’S ARESTAT TECHNOLOGY, AT220, LAUNCHED IN EUROPE First commercial sale triggers milestone payment and future...
Arecor: Business Update
20 juil. 2023 07h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated...
Headline results from Phase I clinical trial of ultra-rapid acting insulin candidate AT247 demonstrate significantly accelerated insulin absorption and early exposure compared to gold standard insulins NovoLog® and Fiasp®
11 oct. 2022 07h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor”, the “Company” or the “Group”) HEADLINE RESULTS FROM PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN CANDIDATE AT247 DEMONSTRATE SIGNIFICANTLY ACCELERATED...
BUSINESS UPDATE
14 juil. 2022 07h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Pipeline for future revenue generating partnered collaborations is strong with further deals anticipated in H2 and beyondKey data for...
ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE
18 mai 2022 07h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE Cambridge, UK, 18 May 2022: Arecor...
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING
28 avr. 2022 07h00 HE
|
Arecor Therapeutics plc
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING Demonstrates best-in-class potential for effective...
Arecor Announces Oral Presentation at Attd 2022 of Phase i Clinical Trial of At278 Ultra-Concentrated Ultra-Rapid Acting Insulin for Diabetes
12 avr. 2022 07h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR ANNOUNCES ORAL PRESENTATION AT ATTD 2022 OF PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES ...
ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS
23 mars 2022 08h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS Further strengthens the Company’s extensive patent portfolio protecting its...